ZYMFENTRA: payments to doctors
Payments that named ZYMFENTRA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.6M
- Providers
- 3,815
- Transactions
- 7,301
- Average per transaction
- $216
The per-transaction average — $216 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 3,815 providers the average total is $413, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Celltrion USA Inc. | $1,559,869 | 99.1% |
| Celltrion Healthcare Canada Ltd. | $14,671 | 0.9% |